Chrissobolis Sophocles, Sobey Christopher G
Department of Pharmacology, University of Melbourne, Parkville, Victoria, Australia.
Stroke. 2002 Jun;33(6):1692-7. doi: 10.1161/01.str.0000016966.89226.67.
The structurally related, inwardly rectifying K+ (K(IR)) channel and the ATP-sensitive K+ (K(ATP)) channel are important modulators of cerebral artery tone. Although protein kinase C (PKC) activators have been shown to inhibit these channels with the use of patch-clamp electrophysiology, effects of PKC on K+ channel function in intact cerebral blood vessels are unknown. We therefore tested whether pharmacological alteration of PKC activity affects cerebral vasodilator responses to K(IR) and/or K(ATP) channel activators in vivo.
We measured changes in basilar artery diameter using a cranial window preparation in anesthetized rats. In addition, intracellular recordings of smooth muscle membrane potential were made in isolated basilar arteries.
K+ (5 to 15 mmol/L) and aprikalim (1 to 10 micromol/L) each elicited reproducible vasodilatation. The PKC activator phorbol-12,13-dibutyrate (PdBu) (50 nmol/L) inhibited responses to K+ (by 40% to 55%) and aprikalim (by 40% to 70%), whereas responses to papaverine were unaffected. The PKC inhibitor calphostin C (0.1 micromol/L) augmented responses to K+ (by 2- to 3-fold) and aprikalim (2-fold) but not papaverine. In addition, K+ (5 mmol/L) and aprikalim (3 micromol/L) each hyperpolarized the basilar artery. PdBu inhibited these responses to aprikalim by 45% but had no effect on K+-induced hyperpolarization.
These data suggest that both basal and stimulated PKC activity inhibit K(IR) and K(ATP) channel-mediated cerebral vasodilatation in vivo. The inhibitory effect on K(ATP) channel-mediated vasodilatation occurs at least partly by inhibition of hyperpolarization mediated by K(ATP) channels. PKC inhibits K+-induced vasodilatation without affecting hyperpolarization, suggesting that the inhibitory effect of PKC on vasodilator responses to K+ does not involve altered K(IR) channel function.
结构相关的内向整流钾离子(K(IR))通道和三磷酸腺苷敏感性钾离子(K(ATP))通道是脑动脉张力的重要调节因子。尽管蛋白激酶C(PKC)激活剂已被证明在使用膜片钳电生理学方法时可抑制这些通道,但PKC对完整脑血管中钾离子通道功能的影响尚不清楚。因此,我们测试了PKC活性的药理学改变是否会影响体内脑动脉对K(IR)和/或K(ATP)通道激活剂的舒张反应。
我们在麻醉大鼠中使用颅窗制备法测量基底动脉直径的变化。此外,在分离的基底动脉中进行平滑肌膜电位的细胞内记录。
钾离子(5至15 mmol/L)和阿普卡林(1至10 μmol/L)均可引起可重复的血管舒张。PKC激活剂佛波醇-12,13-二丁酸酯(PdBu)(50 nmol/L)抑制对钾离子的反应(降低40%至55%)和对阿普卡林的反应(降低40%至70%),而对罂粟碱的反应不受影响。PKC抑制剂钙泊三醇C(0.1 μmol/L)增强对钾离子的反应(增加2至3倍)和对阿普卡林的反应(增加2倍),但对罂粟碱无影响。此外,钾离子(5 mmol/L)和阿普卡林(3 μmol/L)均可使基底动脉超极化。PdBu抑制对阿普卡林的这些反应达45%,但对钾离子诱导的超极化无影响。
这些数据表明,基础和刺激状态下的PKC活性均抑制体内K(IR)和K(ATP)通道介导的脑动脉舒张。对K(ATP)通道介导的血管舒张的抑制作用至少部分是通过抑制K(ATP)通道介导的超极化来实现的。PKC抑制钾离子诱导的血管舒张而不影响超极化,这表明PKC对血管舒张反应的抑制作用不涉及K(IR)通道功能的改变。